Effect of Epalrestat Combined with Liraglutide on T Cell Subsets and Serum Inflammatory Factors in Patients with Type 2 Diabetes Mellitus and Coronary Heart Disease
Objective To investigate the efficacy of epalrestat combined with liraglutide in patients with type 2 diabetes mellitus(T2DM)and coronary heart disease(CHD).Methods A total of 100 patients with T2DM complicated with CHD admitted to Xuchang People's Hospital from March 2020 to June 2023 were selected as the study objects,and were randomly divided into control group(red ball)and study group(blue ball)according to the two-color sphere method,with 50 cases each.The control group was treated with liraglutide,and the study group was treated with liraglutide combined with epalrestat.The clinical efficacy,cardiac function indicators(LVEF,E/A),blood glucose indicators(2 hPG,FPG),Inflammatory factors(TNF-α,CRP,IL-4,IL-6),T cell subsets(CD3+,CD4+,CD8+,CD4+/CD8+)and adverse reactions were compared between the two groups.Results The efficacy of the study group was 96.00%higher than that of the control group 82.00%(P<0.05).After treatment,compared with the control group,the levels of FPG and 2 hPG in the study group were lower,and the levels of LVEF and E/A were higher(P<0.05);the levels of CD3+,CD4+/CD8+and CD4+in study group were higher than those in control group(P<0.05);the levels of TNF-α,CRP and IL-6 in the study group were lower than those in the control group,and the levels of IL-4 were higher than those in the control group(P<0.05).There were no significant differences in CD8+level and incidence of adverse reactions between 2 groups after treatment(P>0.05).Conclusion Epalrestat combined with liraglutide is effective in the treatment of T2DM patients with CHD.It can inhibit the expression of pro-inflammatory factors,enhance immune function and cardiac function,effectively control sugar,and is safe.
NETL
NSTL
万方数据
